Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Revlimid Approved For Use In Relapsed Multiple Myeloma Patients In Japan

Home/Revlimid Approved For Use In Relapsed Multiple Myeloma Patients In Japan

Revlimid Approved For Use In Relapsed Multiple Myeloma Patients In Japan

Celgene’s Revlimid is slowly gaining world wide acceptance as a standard of care for relapsed multiple myleloma patients.  It was announced yesterday Japan has officially approved Revlimid’s use:

REVLIMID® Granted Approval for Treatment of Relapsed or Refractory Multiple Myeloma in Japan

Read all about it on Business Wire.com.  My question:  Why is it taking so long to get American approval for the use of Revlimid for newly diagnosed multiple myeloma patients?  Myeloma docs have been using it “off label” in newly diagnosed patients for four years.
 
Hope it doesn’t take this long to get the next best, new and improved thalidomide based drug, pomalidomide approved! 
 
Feel good and keep smiling!  Pat